Steward Partners Investment Advisory’s Maze Therapeutics MAZE Stock Holding History

Steward Partners Investment Advisory’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49K	Buy	+50	New	+$1.31K	﹤0.01%	4305

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Steward Partners Investment Advisory's MAZE Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 50 shares worth $1.49K. The stake represents ﹤0.01% of the portfolio and ranks #4305 among its holdings.

151 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

Steward Partners Investment Advisory held 50 shares of Maze Therapeutics worth $1.49K as of Q2 2026.
Maze Therapeutics was a new Steward Partners Investment Advisory position in Q2 2026.
Maze Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4305 holding.
151 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.